Efficacy and safety of CD19 CAR T-cell therapy in relapsed/refractory follicular lymphoma: A systematic review and meta-analysis.

What was studied

This review pooled studies of CD19 CAR T-cell therapy. It covered follicular lymphoma that came back or did not respond. The authors searched several databases. They found 2303 records. Of these, 6 studies met the entry rules. The review looked at response, survival, how long responses lasted and side effects. It was registered in a public review registry.

What they found

The pooled response rate was high. The pooled complete response rate was also high. Cytokine release syndrome of any grade was common. Neurological events also occurred. The range around the rate of neurological events was wide. Prior therapy lines and CAR design explained some differences between studies.

What it means for patients

The authors say CAR T-cell therapy showed high efficacy with generally acceptable safety. They say it may be an option for patients with few treatment choices. They say more research on long-term outcomes is needed.

Why it is not certain yet

Only 6 studies were pooled. Studies differed in prior therapy and CAR design. The abstract does not give long-term results. Side effects were common. A review can only be as good as the studies in it.

Source

Efficacy and safety of CD19 CAR T-cell therapy in relapsed/refractory follicular lymphoma: A systematic review and meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.